Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company developing precision drug delivery platforms, today announced it has been awarded an up to $9.6 million grant from the Gates Foundation to advance a subcutaneous, ultra-long-acting antiretroviral (ARV) implant for HIV pre-exposure prophylax…READ FULL ARTICLE
